These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11237260)

  • 21. Kinetics of interactions between DNA and topoisomerase II in the presence of physiologically active effectors.
    Favorov PV; Yakubovskaya EA; Reshetnyak AV; Gabibov AG
    Dokl Biochem; 2000; 370(1-6):38-41. PubMed ID: 11977249
    [No Abstract]   [Full Text] [Related]  

  • 22. Topoisomerase II-dependent novel antitumor compounds merocil and merodantoin induce apoptosis in Daudi cells.
    Gulliya KS; Franck B; Schneider U; Sharma R; Arnold L; Matthews JL
    Anticancer Drugs; 1994 Oct; 5(5):557-66. PubMed ID: 7858288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bacteriophage T4, a model system for understanding the mechanism of type II topoisomerase inhibitors.
    Kreuzer KN
    Biochim Biophys Acta; 1998 Oct; 1400(1-3):339-47. PubMed ID: 9748648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor activity of bent metallocenes: electronic structure analysis using DFT computations.
    Senthilnathan D; Vaideeswaran S; Venuvanalingam P; Frenking G
    J Mol Model; 2011 Mar; 17(3):465-75. PubMed ID: 20495841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and antitumor activity of novel benzimidazole-5-carboxylic acid derivatives and their transition metal complexes as topoisomerease II inhibitors.
    Galal SA; Hegab KH; Hashem AM; Youssef NS
    Eur J Med Chem; 2010 Dec; 45(12):5685-91. PubMed ID: 20884089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action.
    Perrin D; van Hille B; Barret JM; Kruczynski A; Etiévant C; Imbert T; Hill BT
    Biochem Pharmacol; 2000 Apr; 59(7):807-19. PubMed ID: 10718339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Makaluvamines vary in ability to induce dose-dependent DNA cleavage via topoisomerase II interaction.
    Matsumoto SS; Haughey HM; Schmehl DM; Venables DA; Ireland CM; Holden JA; Barrows LR
    Anticancer Drugs; 1999 Jan; 10(1):39-45. PubMed ID: 10194546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors.
    Skladanowski A; Plisov SY; Konopa J; Larsen AK
    Mol Pharmacol; 1996 May; 49(5):772-80. PubMed ID: 8622625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents.
    O'Reilly EK; Kreuzer KN
    Biochemistry; 2002 Jun; 41(25):7989-97. PubMed ID: 12069589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcription generates positively and negatively supercoiled domains in the template.
    Wu HY; Shyy SH; Wang JC; Liu LF
    Cell; 1988 May; 53(3):433-40. PubMed ID: 2835168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enantiomeric specificity of biologically significant Cu(II) and Zn(II) chromone complexes towards DNA.
    Arjmand F; Jamsheera A; Afzal M; Tabassum S
    Chirality; 2012 Dec; 24(12):977-86. PubMed ID: 23001645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes.
    Wilstermann AM; Osheroff N
    Curr Top Med Chem; 2003; 3(3):321-38. PubMed ID: 12570766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topoisomerase II antagonism and anticancer activity of coordinated derivatives of [RuCl(2)(C(6)H(6))(dmso)].
    Vashisht Gopal YN; Konuru N; Kondapi AK
    Arch Biochem Biophys; 2002 May; 401(1):53-62. PubMed ID: 12054487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of DNA topoisomerase II catalytic activity by the antiviral agents 7-chloro-1,3-dihydroxyacridone and 1,3,7-trihydroxyacridone.
    Vance JR; Bastow KF
    Biochem Pharmacol; 1999 Aug; 58(4):703-8. PubMed ID: 10413309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
    Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
    Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis of carbazole derivatives containing chalcone analogs as non-intercalative topoisomerase II catalytic inhibitors and apoptosis inducers.
    Li PH; Jiang H; Zhang WJ; Li YL; Zhao MC; Zhou W; Zhang LY; Tang YD; Dong CZ; Huang ZS; Chen HX; Du ZY
    Eur J Med Chem; 2018 Feb; 145():498-510. PubMed ID: 29335211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Supercondensed structure of plasmid pBR322 DNA in an Escherichia coli DNA topoisomerase II mutant.
    Huang XT; Chen X
    J Mol Biol; 1990 Nov; 216(2):195-9. PubMed ID: 2174973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topoisomerase II poisoning and antineoplastic action by DNA-nonbinding diacetyl and dicarboxaldoxime derivatives of ferrocene.
    Vashisht Gopal YN; Jayaraju D; Kondapi AK
    Arch Biochem Biophys; 2000 Apr; 376(1):229-35. PubMed ID: 10729210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of ring D in the antitumour antibiotic streptonigrin: metal complexation, DNA binding and topoisomerase inhibition by ABC ring analogues of streptonigrin.
    Anderberg PI; Harding MM
    Anticancer Drug Des; 2001; 16(2-3):143-53. PubMed ID: 11962512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual topoisomerase I and II poisoning by chiral Ru(II) complexes containing 2-thiophenylimidazo[4,5-f][1,10]phenanthroline derivatives.
    Wang YC; Qian C; Peng ZL; Hou XJ; Wang LL; Chao H; Ji LN
    J Inorg Biochem; 2014 Jan; 130():15-27. PubMed ID: 24145066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.